The Carlow facility serves as a filling site for vaccines, biologics, and small molecule drug products. Established in 2008, it was MSD’s first vaccines operation outside of the US.

The Dunboyne facility is MSD's first facility for the commercialization of single-use biologics and plays an important role in the commercialization of important medicines and will significantly reduce the time to market for a drug, the company said.

Sanat Chattopadhyay, executive vice president and president of MSD’s manufacturing division, said: “Our MSD Carlow expansion and new MSD Dunboyne facility are both pivotal components of our global operations. These two facilities will yield substantial enhancements to our manufacturing capabilities, enabling our global network to better address the always-evolving demand for vaccines and medicines worldwide.”

Marie Martin, site lead at MSD Carlow, added: “Today’s announcement is a testament to the talent, hard work, and commitment of our team in Carlow and our colleagues across Ireland and internationally, who truly take our mission to Invent for Life to the next level every single day. Over the past 15 years, we are proud to have built a world-class center of excellence for MSD in Carlow.”

“Today marks a significant milestone in MSD Dunboyne’s journey as we officially open our new, state-of-the-art facility. At MSD, our focus is always on the patient and by harnessing the expertise and synergy between our exceptional research and manufacturing teams, we are not only shortening the timeline for drug development but also creating healthier, happier futures for patients worldwide,” added Eva Gallagher, site lead at MSD Dunboyne.